Clinical Trials Browser

Phase 3 × Lymphoma, Non-Hodgkin × Bendamustine Hydrochloride × Clear all

NCT06191744 2026-03-03

EPCORE™FL-2

Phase 3 Recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Phase 3 Active not recruiting

635 enrolled 1 FDA

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT05023980 2026-01-22

BRUIN CLL-313

Phase 3 Active not recruiting

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04002297 2025-09-26

MANGROVE

Phase 3 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT02626455 2024-12-11

CHRONOS-4

Phase 3 Terminated

551 enrolled 32 charts

Lymphoma, Non-Hodgkin

NCT04745832 2024-11-04

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Phase 3 Terminated

82 enrolled 11 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT01456351 2024-08-22

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

Phase 3 Completed

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT06205290 2024-04-02

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Phase 3 Withdrawn

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01596621 2023-05-26

A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment

Phase 3 Completed

102 enrolled 21 charts

Lymphoma, Non-Hodgkin

NCT01332968 2022-08-11

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Phase 3 Completed

1,401 enrolled 40 charts

Lymphoma, Non-Hodgkin

NCT01059630 2020-01-13

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

Phase 3 Completed

413 enrolled 34 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT00877006 2018-02-05

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Phase 3 Completed

447 enrolled 24 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT01724021 2018-01-23

A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

Phase 3 Completed

743 enrolled 16 charts

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00139841 2014-05-09

Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

Phase 3 Completed

Lymphoma, Non-Hodgkin

NCT01570049 2012-08-02

Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma

Phase 3 Unknown

Lymphoma, Non-Hodgkin